- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07660224
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Thalassemia (MITAS)
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Beta-Thalassemia Major
Beta-thalassemia major is a chronic hereditary blood disorder that requires lifelong treatment, including regular blood transfusions and iron chelation therapy. Poor adherence to treatment remains a significant challenge and may lead to iron overload and related complications. Self-efficacy is an important factor influencing patients' ability to adhere to treatment recommendations.
This study aims to evaluate the effect of nurse-delivered Motivational Interviewing (MI) on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. A pre-experimental one-group repeated-measures design will be used. Approximately 45 participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation and Royal Hospital in Muscat, Oman.
Participants will receive three individualized MI sessions over a period of six to eight weeks. Treatment adherence and self-efficacy will be assessed at baseline, immediately after completion of the intervention, and at three-month follow-up. Secondary outcomes include serum ferritin level and frequency of thalassemia-related hospital admissions. The findings will provide evidence regarding the usefulness of motivational interviewing in improving adherence-related outcomes among adults with beta-thalassemia major.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Beta-thalassemia major is a lifelong transfusion-dependent condition that requires continuous adherence to iron chelation therapy to prevent iron overload and its associated complications. Despite advances in treatment, suboptimal adherence remains common among adults with beta-thalassemia major and contributes to increased morbidity and healthcare utilization. Self-efficacy has been identified as a key determinant of adherence behavior and may be enhanced through behavioral interventions.
This study will evaluate the effectiveness of a nurse-delivered Motivational Interviewing (MI) intervention on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. The study is guided by Social Cognitive Theory and uses a quantitative pre-experimental one-group repeated-measures design.
Eligible participants will be adults aged 18 years and older with beta-thalassemia major who are receiving regular follow-up and iron chelation therapy. Participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation, University Medical City, and Royal Hospital in Muscat, Oman.
The intervention consists of three individual motivational interviewing sessions delivered by a trained nurse over six to eight weeks. Each session will last approximately 30 minutes and will focus on exploring treatment-related challenges, enhancing motivation, strengthening self-efficacy, and supporting adherence to iron chelation therapy.
Primary outcomes include treatment adherence measured using the Arabic version of the Adherence to Refills and Medications Scale (ARMS) and self-efficacy measured using the Arabic version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS). Assessments will be conducted at baseline, immediately after the intervention, and three months after completion of the intervention.
Secondary outcomes include changes in serum ferritin levels and thalassemia-related hospital admission frequency. Data will be analyzed using descriptive statistics and repeated-measures statistical tests to examine changes across study time points.
The results of this study may support the integration of motivational interviewing into routine nursing practice for adults with beta-thalassemia major and contribute to improving patient-centered chronic disease management in Oman.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Mizna Said Al-sinani, RN, BSN
- Número de telefone: 968-99851427
- E-mail: s100722@student.squ.edu.om
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adults aged 18 years and older.
- Diagnosed with transfusion-dependent beta-thalassemia major.
- Receiving iron chelation therapy for at least 6 months.
- Receiving regular follow-up at the participating study sites.
- Able to communicate in Arabic or English.
- Willing and able to provide informed consent.
- Able to attend the motivational interviewing sessions and complete study questionnaires.
Exclusion Criteria:
- Current hospitalization for an acute medical condition at the time of recruitment.
- Severe cognitive impairment or psychiatric illness that may affect participation.
- Participation in another structured psychosocial or behavioral intervention program.
- Unable or unwilling to provide informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Motivational Interviewing Intervention
Participants will receive three individual motivational interviewing sessions delivered by a trained nurse over six to eight weeks.
Each session will last approximately 30 minutes and will focus on enhancing treatment adherence, addressing barriers to iron chelation therapy, strengthening self-efficacy, and supporting self-management behaviors.
|
Motivational Interviewing is a patient-centered behavioral intervention designed to enhance intrinsic motivation for behavior change.
Participants will receive three individualized sessions over six to eight weeks focusing on treatment adherence, self-efficacy, goal setting, and management of barriers related to iron chelation therapy.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment Adherence
Prazo: Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Treatment adherence measured using the Arabic version of the Adherence to Refills and Medications Scale (ARMS).
|
Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
|
Self-Efficacy
Prazo: Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Self-efficacy measured using the Arabic version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS).
|
Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Serum Ferritin Level
Prazo: Baseline and 3-month follow-up
|
Change in serum ferritin level following the motivational interviewing intervention.
|
Baseline and 3-month follow-up
|
|
Hospital Admission Frequency
Prazo: Three months before intervention compared with three months after intervention
|
Number of thalassemia-related hospital admissions before and after the intervention.
|
Three months before intervention compared with three months after intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Mizna Said Al-sinani, RN,BSN, Sultan Qaboos University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Genéticas, Congênitas
- Doenças Hematológicas
- Anemia Hemolítica Congênita
- Anemia Hemolítica
- Anemia
- Hemoglobinopatias
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Comportamento
- Doenças hemic e linfáticas
- Comportamento de saúde
- Talassemia
- beta-talassemia
- Adesão e Cumprimento do Tratamento
- Serviços de Saúde
- Instalações de saúde Força e serviços de trabalho
- Disciplinas e atividades comportamentais
- Aconselhamento diretivo
- Aconselhamento
- Serviços de Saúde Mental
- Entrevista motivacional
Outros números de identificação do estudo
- MoH/CSR/26/32221
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .